NASDAQ:IFRX
InflaRx N.V. Stock News
$1.33
-0.0600 (-4.32%)
At Close: Apr 26, 2024
InflaRx N.V. (IFRX) Reports Q4 Loss, Misses Revenue Estimates
09:46am, Thursday, 21'st Mar 2024
InflaRx N.V. (IFRX) came out with a quarterly loss of $0.30 per share versus the Zacks Consensus Estimate of a loss of $0.20.
InflaRx to Announce Development Plans for INF904 and 2023 Financial Results on March 21, 2024
07:30am, Tuesday, 19'th Mar 2024
JENA, Germany, March 19, 2024 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced
Here's Why InflaRx N.V. (IFRX) Looks Ripe for Bottom Fishing
11:18am, Friday, 01'st Dec 2023
InflaRx N.V. (IFRX) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately.
After Plunging -17.65% in 4 Weeks, Here's Why the Trend Might Reverse for InflaRx N.V. (IFRX)
11:17am, Tuesday, 28'th Nov 2023
InflaRx N.V. (IFRX) is technically in oversold territory now, so the heavy selling pressure might have exhausted.
InflaRx N.V. (IFRX) Loses -47.13% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
11:19am, Monday, 06'th Nov 2023
InflaRx N.V. (IFRX) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it.
InflaRx: Small German Company Targeting A Rare Indication
05:31pm, Wednesday, 06'th Sep 2023
InflaRx is a developer of complement mediated therapies for inflammatory diseases. Their lead asset, vilobelimab, is a C5a inhibitor targeting Pyoderma Gangraenosum in a phase 3 trial. The company has
InflaRx (IFRX) Skyrockets 110% in Six Months: Here's Why
03:47pm, Friday, 01'st Sep 2023
Shares of InflaRx (IFRX) show an upward trajectory after it obtained authorization for its first-ever marketed drug, which is approved for the treatment of critically ill COVID-19 patients.
Why InflaRx Stock Skyrocketed This Week
10:21am, Friday, 07'th Apr 2023
InflaRx stock has soared on news that the company's Gohibic drug had received Emergency Use Authorization from the FDA. Analysts expect that Gohibic will be priced above $20,000 per treatment course.
InflaRx shares pop on FDA emergency use authorization of Covid-19 treatment injection
03:51pm, Wednesday, 05'th Apr 2023
The US Food and Drug Administration (FDA) granted emergency-use authorization (EUA) to InflaRx NV's monoclonal antibody for the treatment of hospitalized Covid-19 patients, sending the company's stoc
InflaRx (IFRX) Stock Up on FDA's EUA for COVID-19 Treatment
12:12pm, Wednesday, 05'th Apr 2023
InflaRx (IFRX) shares gain as it receives emergency-use authorization from the FDA for Gohibic (vilobelimab) to treat COVID-19 in terminally-ill patients.
Why Shares of InflaRx Are Soaring Wednesday
11:57am, Wednesday, 05'th Apr 2023
InflaRx is a clinical-stage biotech that focuses on anti-inflammation therapies. Its lead therapy is also seen as a treatment for several skin disorders.
InflaRx (IFRX) Stock Pops as FDA Grants Emergency Use Authorization
10:06am, Wednesday, 05'th Apr 2023
InflaRx (NASDAQ: IFRX ) stock is getting a boost on Wednesday following an update from the FDA concerning its Covid-19 treatment. The big news investors are celebrating today is vilobelimab getting Em
InflaRx: On Watch For A Buy During Tax Loss Selling Season
02:34am, Wednesday, 14'th Dec 2022
IFRX has been beaten down much like many other biotech companies. The company has a lead drug which is being considered for EUA in the US and use in the EU for critical covid.
InflaRx to Present at Upcoming Scientific and Investor Conferences
07:30am, Friday, 09'th Sep 2022
JENA, Germany, Sept. 09, 2022 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement system,
Here's Why InflaRx N.V. (IFRX) is a Great Momentum Stock to Buy
01:33pm, Wednesday, 17'th Aug 2022
Does InflaRx N.V. (IFRX) have what it takes to be a top stock pick for momentum investors?
